ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Osteoarthritis"

  • Abstract Number: 887 • 2019 ACR/ARP Annual Meeting

    Critical Role of the Cholinergic System Involvement in Osteoarthritis

    Alice Courties1, Ariane Do 1, Sarah Leite 2, Audrey Pigenet 2, Morgane Belle 3, Geoffroy Nourissat 4, Alain Sautet 5, Alain Chedotal 3, Uwe Maskos 6, Francis Berenbaum 7 and Jérémie Sellam 1, 1Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, 2Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, 3Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France, Paris, France, 4Chirurgie orthopédique, Clinique Maussins, Groupe Ramsay générale de santé, 67 rue de Romainville, 75019, Paris, Paris, France, 5Chirurgie orthopédique, AP-HP Hôpital Saint-Antoine, Paris, Paris, France, 6Unité de neurobiologie intégrative des systèmes cholinergiques, CNRS UMR 3571, Institut Pasteur, Paris, Paris, France, 7Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France

    Background/Purpose: The efferent vagus nerve can regulate inflammation via its principal neurotransmitter acetylcholine (ACh), a concept referred as the 'cholinergic anti-inflammatory pathway'. ACh interacts with members of…
  • Abstract Number: 1310 • 2019 ACR/ARP Annual Meeting

    Osteoarthritis: What’s in a Name?

    Warren A Katz1, 1Penn Medicine; University of Pennsylvania School of Medicine, Upper Gwynedd, PA

    Background/Purpose: The nomenclature of "osteoarthritis" (OA) has been a source of confusion and likely misdiagnosis for centuries.  Prior to 1759, most patients with joint diseases…
  • Abstract Number: 1760 • 2019 ACR/ARP Annual Meeting

    Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial

    Féline Kroon1, Marion Kortekaas 1, Annelies Boonen 2, Stephan Böhringer 3, Monique Reijnierse 1, Frits R Rosendaal 3, Naghmeh Riyazi 4, Mirian Starmans 5, Franktien Turkstra 6, Jende van Zeben 7, CF Allaart 8 and Margreet Kloppenburg 3, 1Leiden University Medical Center, Leiden, Netherlands, 2Maastricht University Medical Center, Maastricht, Netherlands, 3Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 4Haga Hospital, The Hague, Netherlands, 5Zuyderland Medical Center, Heerlen, Netherlands, 6Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 7Sint Franciscus Vlietland Groep, Rotterdam, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands

    Background/Purpose: Hand osteoarthritis (OA) is a prevalent joint disease with high disease-burden in need for effective therapeutic options. Studies have shown that synovial inflammation is…
  • Abstract Number: 1985 • 2019 ACR/ARP Annual Meeting

    Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis

    Ricardo Grieshaber-Bouyer1, Till Kämmerer 2, Nils Rosshirt 2, Philipp Koniezke 2, Sebastien Hagmann 2, Elena Tripel 2, Johannes Kirsch 2, Tobias Gotterbarm 2 and Babak Moradi 2, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Department of Orthopedics, Heidelberg University Hospital, Heidelberg, Germany, Boston, MA, 2Department of Orthopedics, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany

    Background/Purpose: Osteoarthritis (OA) is a progressive joint disease driven by a blend of inflammatory and biomechanical processes. Studies using human samples to understand inflammatory mechanisms…
  • Abstract Number: 2184 • 2019 ACR/ARP Annual Meeting

    A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    T Mark Campbell1 and Dennis McGonagle 2, 1Elisabeth Bruyere Hospital, Ottawa, ON, Canada, 2University of Leeds, Leeds, United Kingdom

    Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis. Knee OA is often accompanied by a knee flexion contracture (FC), but the impact of…
  • Abstract Number: 2410 • 2019 ACR/ARP Annual Meeting

    Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable

    Mohammad Atiquzzaman1, Mohammad Karim 2, Jacek Kopec 3, Hubert Wong 4, Mary De Vera 5 and Aslam Anis 2, 1Faculty of Pharmaceutical Sciences, University of British Columbia, Surrey, BC, Canada, 2School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: BMI is a well-known confounding factor in the association between osteoarthritis (OA) and cardiovascular diseases (CVD). However, BMI is not usually recorded in administrative…
  • Abstract Number: 888 • 2019 ACR/ARP Annual Meeting

    Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models

    Morena Scotece1, Ignacio Rego-Pérez 2, Ana Victoria Lechuga-Vieco 3, María Concepción Jiménez Gómez 3, Purificación Filgueira-Fernández 4, José Antonio Enriquez 3 and Francisco J. Blanco 2, 1Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, 2Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 3Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Madrid, Spain, 4Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Galicia, Spain

    Background/Purpose: Accumulated data indicated that osteoarthritis has a strong genetic component with a prevalent role of mitochondria and mtDNA variations. In the present work, we…
  • Abstract Number: 1311 • 2019 ACR/ARP Annual Meeting

    Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study

    Maite Silva-Díaz1, Francisco J. Blanco 2, Victor Quevedo Vila 3, Daniel Seoane-Mato 4, Sagrario Bustabad-Reyes 5 and on behalf of the Working Group Proyecto EPISER2016 6, 1Servicio de Reumatología. Complexo Hospitalario Universitario A Coruña (CHUAC)-INIBIC, A Coruña, Spain, 2Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 3Unidad de Reumatología. Hospital Comarcal Monforte de Lemos., Lugo, Spain, 4Unidad de Investigación. Sociedad Española de Reumatología., Madrid, Spain, 5eumatología. Hospital Universitario de Canarias., La Laguna, Santa Cruz de Tenerife, Spain, 6Grupo de trabajo del proyecto EPISER2016, Madrid, Spain

    Background/Purpose: Osteoarthritis (OA) is a heterogeneous group of diseases with common clinical and radiographic manifestations involving the peripheral and axial skeletal. OA is the most…
  • Abstract Number: 1846 • 2019 ACR/ARP Annual Meeting

    Does Cartilage Loss Cause Pain in Osteoarthritis?

    KATHRYN BACON1, Lavalley Michael 2 and David Felson 3, 1Boston University School of Medicine, Boston, MA, 2Boston University, Boston, 3Boston University School of Medicine, Department of Rheumatology, Boston

    Background/Purpose: Treatment development in osteoarthritis continues to focus on chondroprotection, but it is unclear if delaying cartilage loss would reduce joint pain. In published studies,…
  • Abstract Number: 1988 • 2019 ACR/ARP Annual Meeting

    Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk

    Rocío Castro-Viñuelas1, Clara Sanjurjo-Rodríguez 2, María Piñeiro-Ramil 1, Silvia Rodríguez-Fernández 1, Tamara Hermida-Gómez 3, Francisco J. De Toro 4, Isaac Fuentes-Boquete 1, Francisco J. Blanco 5 and Silvia Díaz-Prado 1, 1Grupo de investigación en Terapia Celular y Medicina Regenerativa. Departamento de Fisioterapia, Medicina y Ciencias Biomédicas. Universidade da Coruña. Agrupación estratégica CICA-INIBIC. A Coruña, España., A Coruña, Spain, 2Grupo de investigación en Terapia Celular y Medicina Regenerativa. Departamento de Fisioterapia, Medicina y Ciencias Biomédicas. Universidade da Coruña. Agrupación estratégica CICA-INIBIC. A Coruña, España; University of Leeds; Newcastle University, A Coruña, Spain, 3Unidad de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Centro de Investigaciones Científicas Avanzadas (CICA), A Coruña, Spain, 4University Hospital A Coruña, A Coruña, Spain, 5Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain

    Background/Purpose: Knowledge and research results in the field of hand osteoarthritis (hOA) are currently limited, mainly due to the unavailability of tissue samples to develop…
  • Abstract Number: 2185 • 2019 ACR/ARP Annual Meeting

    MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up

    C. Kent Kwoh1, Frank Roemer 2, Erin Ashbeck 3, ChengCheng Hu 1, Edward Bedrick 1, Leena Sharma 4 and Ali Guermazi 5, 1University of Arizona, Tucson, AZ, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, 4Northwestern University, Chicago, IL, 5Boston Medical Center, Boston

    Background/Purpose: MRI Osteoarthritis Knee Score (MOAKS) is a semi-quantitative scoring system used to assess MRI-detected structural abnormalities including over 100 raw scores representing multiple joint…
  • Abstract Number: 2756 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

    Marc C. Hochberg1, John Carrino 2, Thomas Schnitzer 3, Ali Guermazi 4, David Walsh 5, Alexander White 6, Satoru Nakajo 7, Robert Fountaine 8, Anne Hickman 8, Glenn Pixton 9, Lars Viktrup 10, Mark T. Brown 8, Christine R. West 8 and Kenneth M. Verburg 8, 1University of Maryland School of Medicine, Baltimore, MD, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Boston Medical Center, Boston, 5Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, 6Progressive Medical Research, Port Orange, FL, 7Nakajo Orthopaedic Clinic, Miyagi, Japan, 8Pfizer Inc, Groton, CT, 9Pfizer Inc, Morrisville, NC, 10Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies,…
  • Abstract Number: 891 • 2019 ACR/ARP Annual Meeting

    Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

    Vishal Deshmukh1, Alyssa O'Green 1, Carine Bossard 1, Tim Seo 1, Lisa Lamangan 1, Maureen Ibanez 1, Abdullah Ghias 1, Carolyn Lai 1, Long Do 1, Shawn Cho 1, Joseph Cahiwat 1, Kevin Chiu 1, Melinda Pedraza 1 and Yusuf Yazici 1, 1Samumed, LLC, San Diego, CA

    Background/Purpose: In the synovial joint, Wnt pathway upregulation contributes to osteoarthritis (OA) by increasing osteocyte differentiation, cartilage thinning, and inflammation. Lorecivivint (LOR; SM04690), a novel…
  • Abstract Number: 1312 • 2019 ACR/ARP Annual Meeting

    Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study

    Anand Ramachandran Nair1, Weiya Zhang 2, Michael Doherty 2 and Abhishek Abhishek 3, 1Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham, UK, Nottingham, England, United Kingdom, 2Academic Rheumatology, Division of Rheumatology,School of Medicine, University of Nottingham, Nottingham, UKArthritis Research UK Pain Centre, Nottingham, UKNational Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK, Nottingham, England, United Kingdom, 3Academic Rheumatology, School of Medicine, University of Nottingham,Nottingham,UK National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham,UK, Nottingham, England, United Kingdom

    Background/Purpose: Although several morphological features of the hip joint predispose to hip osteoarthritis (OA), only a few are known to associate with knee OA. The…
  • Abstract Number: 1878 • 2019 ACR/ARP Annual Meeting

    Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice

    Sebastian Rodriguez-Garcia1, Raul Castellanos-Moreira 2, Jacqueline Uson-Jaeger 3, ESPERANZA NAREDO 4 and Loreto Carmona 5, 1Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, 2Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 3Hospital Universitario de Mostoles, Madrid, Spain, 4Rheumatology Department, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, MADRID, Spain, 5Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain

    Background/Purpose: In recent years, diverse compounds for intra-articular (IA) administration were brought into the market with a subsequent significant and heterogeneous literature production. Understanding the efficacy…
  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 63
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology